Role of aspirin in the primary prevention of cardiovascular disease in diabetes mellitus: a meta-analysis.
OBJECTIVE
To evaluate the benefits of aspirin in people with diabetes mellitus for the primary prevention of cardiovascular disease.


METHODS
We searched MEDLINE and Cochrane database for randomized, controlled trials of aspirin in people with diabetes and no cardiovascular disease. Relative risks were determined using random-effects meta-analysis.


METHODS
Risk reduction of aspirin compared with control groups for major cardiovascular events.


RESULTS
Six trials consisting of 7374 patients with diabetes showed no benefits of aspirin compared with non-aspirin users with regard to overall mortality, risk reduction (relative risk (RR) = 0.96, 95% CI 0.78 - 1.18, p = 0.71), major cardiovascular events (RR = 0.90, 95% CI 0.78 - 1.05, p = 0.17) and myocardial infarction (RR = 0.95, 95% CI 0.76 - 1.18, p = 0.63). Risk of major bleeding in the aspirin compared with the non-aspirin group was not significant (RR = 2.49, 95% CI 0.70 - 8.84, p = 0.16).


CONCLUSIONS
Aspirin therapy did not reduce the risk of cardiovascular events. Existing trials were limited by small patient numbers and low cardiovascular event rates. The use of aspirin cannot be routinely recommended for primary prevention of cardiovascular events in diabetes.
Younis
Naveed
N
University Hospital South Manchester, Wythenshawe Hospital, Department of Diabetes & Endocrinology, Southmoor Road, Manchester M23 9LT, UK. naveed.younis@uhsm.nhs.uk
Williams
Steven
S
Ammori
Basil
B
Soran
Handrean
H
D001241:Aspirin / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000150:complications / Q000517:prevention & control*; D003924:Diabetes Mellitus, Type 2 / Q000150:complications*; D006801:Humans; D011322:Primary Prevention
D001241:Aspirin